Welcome to our dedicated page for Shattuck Labs news (Ticker: STTK), a resource for investors and traders seeking the latest updates and insights on Shattuck Labs stock.
Shattuck Labs, Inc. develops monoclonal and bispecific DR3-blocking antibodies for inflammatory and immune-mediated diseases. The company’s news centers on SL-325, a Death Receptor 3 antibody targeting the DR3/TL1A pathway, with emphasis on clinical development in inflammatory bowel disease and related immune-mediated conditions.
Recurring updates also cover quarterly financial results, cash and capital-structure disclosures, investor conference participation, inducement equity awards, and governance matters tied to Shattuck’s Nasdaq-listed common stock.
Shattuck Labs (NASDAQ: STTK) priced a public offering of 10,879,376 common shares at $4.00 and pre-funded warrants for up to 7,870,624 shares at $3.9999 each. Gross proceeds are expected to be about $75 million before expenses. Closing is expected on June 11, 2026, with underwriters holding a 30-day option to buy up to 2,812,500 additional shares.
Shattuck Labs (NASDAQ: STTK) commenced a proposed public offering of common stock and, for certain investors, pre-funded warrants to purchase common shares. All securities will be offered by Shattuck.
Underwriters are expected to receive a 30-day option to buy up to an additional 15% of shares. The offering’s completion, size and terms remain subject to market and other conditions under an effective SEC registration.
Shattuck Labs (NASDAQ: STTK) reported that holders have exercised or given notices to exercise approximately 50.6 million common stock warrants, about 96% of warrants issued in the August 4, 2025 private placement. This is expected to generate roughly $54.9 million in gross proceeds, including $5.6 million received by March 31, 2026 and an additional $49.3 million anticipated. Combined with $90.4 million in cash, cash equivalents and short-term investments as of March 31, 2026, Shattuck expects to fund operations into 2029, based on current plans.
Shattuck Labs (NASDAQ: STTK) reported Phase 1 results for DR3-blocking antibody SL-325 in 72 healthy volunteers. Only 3.7% (2/54) developed low‑titer antidrug antibodies, with no impact on PK or receptor occupancy. Complete DR3 occupancy occurred at ≥0.1 mg/kg, with TL1A blockade lasting over 10 weeks.
SL-325 showed no DR3 agonism, no cytokine changes, and only Grade 1 treatment-related adverse events, with no serious events. A Phase 2b Crohn’s disease trial is expected to start in Q3 2026, and bispecific candidate SL-846 is progressing through IND-enabling toxicology.
Shattuck Labs (NASDAQ: STTK) will host an investor call and webcast on June 8, 2026 at 8:00 a.m. ET to present comprehensive Phase 1 clinical data for SL-325, a potentially first-in-class DR3 blocking antibody, and provide a pipeline update.
The event will feature Shattuck’s management team and include a Q&A session, with live and replay access via the company’s website.
Shattuck Labs (NASDAQ: STTK) reported Q1 2026 results and program milestones on May 7, 2026. Cash and short-term investments were $90.4M as of March 31, 2026, up from $60.9M a year earlier. Q1 net loss was $14.8M (or $0.13 per share). Enrollment in the Phase 1 trial of SL-325 is complete; full Phase 1 data are expected in Q2 2026 and a Phase 2 trial in Crohn’s disease is planned for Q3 2026. The lead bispecific antibody has entered IND-enabling activities. Cash runway is expected into 2029 assuming full exercise of outstanding warrants.
Shattuck Labs (NASDAQ: STTK) reported Q4 and full-year 2025 results and program updates. As of Dec 31, 2025 cash and short-term investments were $78.1M; preliminary Feb 28, 2026 cash was $94.5M after $21.4M ATM sales. Q4 R&D fell to $9.1M (Q4 2024: $15.4M); full‑year R&D was $35.3M (2024: $67.2M). Net loss improved to $48.8M for 2025 (2024: $75.4M).
Clinical: Phase 1 SL-325 trial is nearly complete with data expected in Q2 2026; Phase 2 in Crohn’s disease is planned to begin in Q3 2026, subject to positive Phase 1 data and regulatory alignment. Lead bispecific entered IND-enabling activities.
Shattuck Labs (NASDAQ: STTK) announced CEO Taylor Schreiber, M.D., Ph.D., will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026 at 9:10 AM ET in Boston and hold one-on-one meetings at the Leerink Partners 2026 Global Health Care Conference March 10-11 in Miami.
Live audio webcasts will be available via the company's Investor Relations website, with replay accessible for about 30 days after each presentation.
Shattuck Labs (NASDAQ: STTK) will present a prerecorded fireside chat at the Piper Sandler Virtual Novel Targets in Immunology Symposium on February 12, 2026 at 2:00 PM ET. Presenters include Taylor Schreiber, M.D., Ph.D. (CEO), Andrew R. Neill (CFO), and Michael Choi, M.D. (VP Clinical Development).
A replay of the prerecorded presentation will be available on the company’s Events and Presentations webpage starting at 2:00 PM ET on February 12, 2026, and will be archived for up to 30 days following the presentation date.
Shattuck Labs (NASDAQ: STTK) granted inducement equity awards on Dec 10, 2025 to a newly hired non-executive officer under Nasdaq Listing Rule 5635(c)(4).
The awards are non-qualified stock options to purchase 206,000 shares at an exercise price of $3.23 per share, with a maximum term of 10 years. Vesting is 25% on Nov 17, 2026 and the remainder vests in equal monthly installments over the following 36 months. The awards were granted outside the Company’s 2020 Equity Incentive Plan but are generally subject to the same terms and were approved by the independent Compensation Committee.